Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
The invention provides pharmaceutical compositions comprising a compound of formula (I) or (II) and an additional therapeutic agent Also provided is the HCI salt and crystalline form of the compound of formula (I). The compounds inhibit the prostaglandin F receptor (PGF2alpha) and thus useful in the treatment of disorders such as preterm labor at the early gestational stage.
1. A method of treating preterm labor in a human patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a compound represented by formula (I),
or a pharmaceutically acceptable salt thereof, and wherein the patient is further administered nifedipine.
2. A method of delaying labor in a human patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a compound represented by formula (I),
or a pharmaceutically acceptable salt thereof, and wherein the patient is further administered nifedipine.
3. A method of delaying labor prior to cesarean delivery in a human patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a compound represented by formula (I),
or a pharmaceutically acceptable salt thereof, and wherein the patient is further administered nifedipine.
4. The method of claim 1 , wherein the compound is represented by formula (III)
5. The method of claim 4 , wherein the compound is in a crystalline state.
6. The method of claim 5 , wherein the compound exhibits characteristic X-ray powder diffraction peaks at about 7.0° 2θ, about 8.1° 2θ, about 10.0° 2θ, about 12.0° 2θ, about 13.1° 2θ, about 14.1° 2θ, about 16.4° 2θ, about 18.4° 2θ, about 20.1° 2θ, about 21.0° 2θ, about 23.5° 2θ, and about 29.5° 2θ.
7. The method of claim 6 , wherein the compound is characterized by an X-ray powder diffraction spectrum substantially as depicted in FIG. 49 .
8. The method of claim 5 , wherein the compound exhibits 1 H nuclear magnetic resonance (NMR) peaks centered at about 1.1 ppm, about 3.3 ppm, about 4.9 ppm, about 5.4 ppm, about 7.1 ppm, about 7.7 ppm, about 7.9 ppm, and about 8.0 ppm.
9. The method of claim 8 , wherein the compound is characterized by a 1 H NMR spectrum substantially as depicted in FIG. 21 .
10. The method of claim 5 , wherein the compound exhibits an endotherm at from about 145° C. to about 147° C. as measured by differential scanning calorimetry.
11. The method of claim 10 , wherein the compound is characterized by a differential scanning calorimetry curve substantially as depicted in FIG. 20 or FIG. 23 .
12. The method of claim 1 , wherein the compound exhibits a weight loss of from about 0.2% to about 0.6% when heated from 25° C. to 100° C. as measured by thermogravimetric analysis.
13. The method of claim 12 , wherein the compound exhibits a thermogravimetric analysis curve substantially as depicted in FIG. 24 .
14. The method of claim 1 , wherein the patient is further administered a betamimetic, a magnesium salt, a nitric oxide donor, progesterone or a variant thereof, or a corticosteroid.
15. The method of claim 1 , wherein the patient is further administered a betamimetic selected from the group consisting of terbutaline, ritodrine, hexoprenaline, albuterol, fenoterol, nylidrin, and orciprenaline.
16. The method of claim 1 , wherein the patient is further administered magnesium sulfate.
17. The method of claim 1 , wherein the patient is further administered nitroglycerine.
18. The method of claim 1 , wherein the patient is further administered progesterone or 17-α-hydroxyprogesterone caproate.
19. The method of claim 1 , wherein the patient is further administered a corticosteroid selected from the group consisting of betamethasone, dexamethasone, and hydrocortisone.
20. The method of claim 1 , wherein the compound is administered to the patient orally.
21. The method of claim 1 , wherein the patient is characterized by a gestational age of from about 24 weeks to about 34 weeks.
22. The method of claim 1 , wherein the patient exhibits a reduction in the amplitude of uterine contractions following administration of the compound to the patient.
23. The method of claim 2 , wherein the compound is represented by formula (III)
24. The method of claim 23 , wherein the compound is in a crystalline state.
25. The method of claim 24 , wherein the compound exhibits characteristic X-ray powder diffraction peaks at about 7.0° 2θ, about 8.1° 2θ, about 10.0° 2θ, about 12.0° 2θ, about 13.1° 2θ, about 14.1° 2θ, about 16.4° 2θ, about 18.4° 2θ, about 20.1° 2θ, about 21.0° 2θ, about 23.5° 2θ, and about 29.5° 2θ.
26. The method of claim 25 , wherein the compound is characterized by an X-ray powder diffraction spectrum substantially as depicted in FIG. 49 .
27. The method of claim 24 , wherein the compound exhibits 1 H nuclear magnetic resonance (NMR) peaks centered at about 1.1 ppm, about 3.3 ppm, about 4.9 ppm, about 5.4 ppm, about 7.1 ppm, about 7.7 ppm, about 7.9 ppm, and about 8.0 ppm.
28. The method of claim 27 , wherein the compound is characterized by a 1 H NMR spectrum substantially as depicted in FIG. 21 .
29. The method of claim 24 , wherein the compound exhibits an endotherm at from about 145° C. to about 147° C. as measured by differential scanning calorimetry.
30. The method of claim 29 , wherein the compound is characterized by a differential scanning calorimetry curve substantially as depicted in FIG. 20 or FIG. 23 .
31. The method of claim 24 , wherein the compound exhibits a weight loss of from about 0.2% to about 0.6% when heated from 25° C. to 100° C. as measured by thermogravimetric analysis.
32. The method of claim 31 , wherein the compound exhibits a thermogravimetric analysis curve substantially as depicted in FIG. 24 .
33. The method of claim 2 , wherein the patient is further administered a betamimetic, a magnesium salt, a nitric oxide donor, progesterone or a variant thereof, or a corticosteroid.
34. The method of claim 2 , wherein the patient is further administered a betamimetic selected from the group consisting of terbutaline, ritodrine, hexoprenaline, albuterol, fenoterol, nylidrin, and orciprenaline.
35. The method of claim 2 , wherein the patient is further administered magnesium sulfate.
36. The method of claim 2 , wherein the patient is further administered nitroglycerine.
37. The method of claim 2 , wherein the patient is further administered progesterone or 17-α-hydroxyprogesterone caproate.
38. The method of claim 2 , wherein the patient is further administered a corticosteroid selected from the group consisting of betamethasone, dexamethasone, and hydrocortisone.
39. The method of claim 2 , wherein the compound is administered to the patient orally.
40. The method of claim 2 , wherein the patient is characterized by a gestational age of from about 24 weeks to about 34 weeks.
41. The method of claim 2 , wherein the patient exhibits a reduction in the amplitude of uterine contractions following administration of the compound to the patient.
42. The method of claim 3 , wherein the compound is represented by formula (III)
43. The method of claim 42 , wherein the compound is in a crystalline state.
44. The method of claim 43 , wherein the compound exhibits characteristic X-ray powder diffraction peaks at about 7.0° 2θ, about 8.1° 2θ, about 10.0° 2θ, about 12.0° 2θ, about 13.1° 2θ, about 14.1° 2θ, about 16.4° 2θ, about 18.4° 2θ, about 20.1° 2θ, about 21.0° 2θ, about 23.5° 2θ, and about 29.5° 2θ.
45. The method of claim 44 , wherein the compound is characterized by an X-ray powder diffraction spectrum substantially as depicted in FIG. 49 .
46. The method of claim 43 , wherein the compound exhibits 1 H nuclear magnetic resonance (NMR) peaks centered at about 1.1 ppm, about 3.3 ppm, about 4.9 ppm, about 5.4 ppm, about 7.1 ppm, about 7.7 ppm, about 7.9 ppm, and about 8.0 ppm.
47. The method of claim 46 , wherein the compound is characterized by a 1 H NMR spectrum substantially as depicted in FIG. 21 .
48. The method of claim 43 , wherein the compound exhibits an endotherm at from about 145° C. to about 147° C. as measured by differential scanning calorimetry.
49. The method of claim 48 , wherein the compound is characterized by a differential scanning calorimetry curve substantially as depicted in FIG. 20 or FIG. 23 .
50. The method of claim 43 , wherein the compound exhibits a weight loss of from about 0.2% to about 0.6% when heated from 25° C. to 100° C. as measured by thermogravimetric analysis.
51. The method of claim 50 , wherein the compound exhibits a thermogravimetric analysis curve substantially as depicted in FIG. 24 .
52. The method of claim 3 , wherein the patient is further administered a betamimetic, a magnesium salt, a nitric oxide donor, progesterone or a variant thereof, or a corticosteroid.
53. The method of claim 3 , wherein the patient is further administered a betamimetic selected from the group consisting of terbutaline, ritodrine, hexoprenaline, albuterol, fenoterol, nylidrin, and orciprenaline.
54. The method of claim 3 , wherein the patient is further administered magnesium sulfate.
55. The method of claim 3 , wherein the patient is further administered nitroglycerine.
56. The method of claim 3 , wherein the patient is further administered progesterone or 17-α-hydroxyprogesterone caproate.
57. The method of claim 3 , wherein the patient is further administered a corticosteroid selected from the group consisting of betamethasone, dexamethasone, and hydrocortisone.
58. The method of claim 3 , wherein the compound is administered to the patient orally.
59. The method of claim 3 , wherein the patient is characterized by a gestational age of from about 24 weeks to about 34 weeks.
60. The method of claim 3 , wherein the patient exhibits a reduction in the amplitude of uterine contractions following administration of the compound to the patient.